| A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIV (NCT07698600) | BioNTech SE | 2026-07-01 |
| A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer (NCT07365995) | BioNTech SE | 2026-04-22 |
| Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors (NCT07455734) | BioNTech SE | 2026-03-30 |
| A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa (NCT07379580) | BioNTech SE | 2026-02-20 |
| A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV (NCT07392372) | BioNTech SE | 2026-02-09 |
| A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma (NCT07297212) | BioNTech SE | 2026-01-15 |
| A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age (NCT07300839) | BioNTech SE | 2025-12-10 |
| A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer (NCT07255404) | BioNTech SE | 2025-12-04 |
| A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9 (NCT07186842) | BioNTech SE | 2025-11-18 |
| A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19 (NCT07222384) | BioNTech SE | 2025-10-30 |
| ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer (NCT07173751) | BioNTech SE | 2025-10-30 |
| A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC) (NCT07111520) | BioNTech SE | 2025-09-22 |
| A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors (NCT07147348) | BioNTech SE | 2025-08-27 |
| A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors (NCT07070232) | BioNTech SE | 2025-08-12 |
| A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer (NCT07079631) | BioNTech SE | 2025-07-18 |
| A Clinical Study Investigating the Therapeutic Effects and Safety of an Investigational Cell Therapy Given With and Without an Additional Investigational Product in Males With Testicular Cancer or a Form of Cancer That Developed From Sperm (NCT06940804) | BioNTech SE | 2025-07-01 |
| A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer (NCT06340568) | BioNTech SE | 2025-06-10 |
| A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer (NCT06892548) | BioNTech SE | 2025-05-02 |
| Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment (NCT06841055) | BioNTech SE | 2025-03-03 |
| A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People (NCT06821061) | BioNTech SE | 2025-02-10 |
| Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer (NCT06712355) | BioNTech SE | 2025-02-03 |
| Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors (NCT06750185) | BioNTech SE | 2025-01-13 |
| Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (NCT06712316) | BioNTech SE | 2025-01-07 |
| A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and Children (NCT05630352) | BioNTech SE | 2025-01-06 |
| A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People (NCT06683352) | BioNTech SE | 2024-11-11 |
| Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy (NCT06449222) | BioNTech SE | 2024-08-26 |
| Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy (NCT06449209) | BioNTech SE | 2024-08-05 |
| A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multiple Ascending Doses in Women Diagnosed With Bacterial Vaginosis (NCT06469164) | BioNTech SE | 2024-07-01 |
| Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma (NCT06069778) | BioNTech SE | 2024-03-27 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza. (NCT06178991) | BioNTech SE | 2023-12-20 |
| Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors (NCT06150183) | BioNTech SE | 2023-11-30 |
| A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria (NCT06069544) | BioNTech SE | 2023-11-13 |
| A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines (NCT05988203) | BioNTech SE | 2023-09-21 |
| A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals (NCT05997290) | BioNTech SE | 2023-08-10 |
| Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers (NCT05547464) | BioNTech SE | 2023-07-31 |
| Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers (NCT05537038) | BioNTech SE | 2023-04-18 |
| Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria (NCT05581641) | BioNTech SE | 2022-12-15 |
| A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions (NCT05432583) | BioNTech SE | 2022-12-08 |
| Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People (NCT05541861) | BioNTech SE | 2022-11-08 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza (NCT05596734) | BioNTech SE | 2022-10-28 |
| A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children (NCT05543616) | BioNTech SE | 2022-09-23 |
| Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer (NCT05142189) | BioNTech SE | 2022-06-17 |
| Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age (NCT05310084) | BioNTech SE | 2022-04-20 |
| Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors (NCT05262530) | BioNTech SE | 2022-03-22 |
| Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors (NCT04683939) | BioNTech SE | 2022-01-18 |
| Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years (NCT04895982) | BioNTech SE | 2021-10-15 |
| Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants (NCT05004181) | BioNTech SE | 2021-08-25 |
| A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects (NCT04949490) | BioNTech SE | 2021-07-26 |
| Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy (NCT04813627) | BioNTech SE | 2021-07-02 |
| To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age. (NCT04955626) | BioNTech SE | 2021-07-01 |
| Dose Escalation Trial of BNT152+153 in Patients With Cancer (NCT04710043) | BioNTech SE | 2021-06-08 |
| A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment (NCT04526899) | BioNTech SE | 2021-05-19 |
| Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children (NCT04816643) | BioNTech SE | 2021-03-24 |
| A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer (NCT04486378) | BioNTech SE | 2021-03-08 |
| To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older (NCT04754594) | BioNTech SE | 2021-02-16 |
| A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants (NCT04713553) | BioNTech SE | 2021-02-15 |
| BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors (NCT04455620) | BioNTech SE | 2021-01-26 |
| A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (NCT04534205) | BioNTech SE | 2021-01-07 |
| Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population (NCT04649021) | BioNTech SE | 2020-12-04 |
| Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults (NCT04588480) | BioNTech SE | 2020-10-21 |
| A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults (NCT04537949) | BioNTech SE | 2020-09-09 |
| Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects (NCT04523571) | BioNTech SE | 2020-07-28 |
| Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 (NCT04101357) | BioNTech SE | 2020-06-19 |
| Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals (NCT04368728) | BioNTech SE | 2020-04-29 |
| A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults (NCT04380701) | BioNTech SE | 2020-04-23 |
| PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy) (NCT04382898) | BioNTech SE | 2019-12-19 |